CClinicalTrials.gg
CompletedNCT06610136Updated Sep 24, 2024

Caffeine and Resistance Training in Young Adults

An interventional study of Caffeine plus Resistance training and Placebo + Resistance training in Caffeine and Resistance Training, sponsored by University of Alcala. Completed at 1 site in Spain. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by University of Alcala · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2023, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, little is known about the prolonged effect of this supplement on neuromuscular adaptations to strength training.

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, little is known about the prolonged effects of this supplement on neuromuscular adaptations to strength training.

Objectives: The present study aims to analyze the effects of acute and chronic caffeine intake on neuromuscular adaptations to strength training, according to sex (men vs. women) and type of exercise (bench press vs. squat), as well as on fatigue resistance during repeated sprints, fatigue perception, mood state, reaction time, diet, and potential side effects.

02

Conditions studied

  • Caffeine and Resistance Training
03

In context

Lead sponsor

University of Alcala is the lead sponsor of 123 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age between ≥ 18 and ≤ 35 years.
  • Body mass index (BMI) \< 25 kg/m².
  • Physically active subjects (>150 min/week of moderate exercise).
  • Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
  • Participants capable of performing the tests.

Exclusion criteria

Exclusion Criteria:

  • History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
  • Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
  • Body mass index (BMI) > 25 kg/m².
  • Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
  • Performing strenuous exercise within 48 hours prior to the tests.
  • Failing to replicate the same food intake on the two experimental days.
  • Consuming caffeine after 6 PM on the day prior to training or testing.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Caffeine - Males

    Dietary Supplement: Caffeine plus Resistance training

  • Placebo comparator
    Placebo - Males

    Other: Placebo + Resistance training

  • Experimental
    Caffeine - Females

    Dietary Supplement: Caffeine plus Resistance training

  • Placebo comparator
    Placebo - Females

    Other: Placebo + Resistance training

Interventions

  • Dietary supplementCaffeine plus Resistance training

    Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

  • OtherPlacebo + Resistance training

    Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

06

What researchers measure

Primary outcomes

  1. Mean velocity at different %1RM

    Measuring bar mean velocity desplacement during bench press and back squat exercises.

    Time frame: Through study completion, an average of 12 weeks

  2. Peak velocity at different %1RM

    Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.

    Time frame: Through study completion, an average of 12 weeks

  3. Mean power output at different %1RM

    Measuring during bench press and back squat exercises.

    Time frame: Through study completion, an average of 12 weeks

  4. Peak power output and time to reach peak power output at different %1RM

    Measuring during bench press and back squat exercises.

    Time frame: Through study completion, an average of 12 weeks

  5. Number of repetitions performed at 65%1RM until task failure

    In bench press and back squat exercises

    Time frame: Through study completion, an average of 12 weeks

  6. Bar velocity deplacement performed in 1 set at 65%1RM until task failure

    In bench press and back squat exercises

    Time frame: Through study completion, an average of 12 weeks

  7. Power output generated in 1 set at 65%1RM until task failure

    In bench press and back squat exercise

    Time frame: Through study completion, an average of 12 weeks

Secondary outcomes

  1. Resting Metabolic Rate (RMR)

    Kcal at rest using a metabolic chart.

    Time frame: Through study completion, an average of 12 weeks

  2. Maximal Fat Oxidation Rate (MFO)

    g/min using a metabolic chart.

    Time frame: Through study completion, an average of 12 weeks

  3. Fat mass

    Using electrical bioimpedance (kg and % of body mass)

    Time frame: Through study completion, an average of 12 weeks

  4. Fat-free mass

    Using electrical bioimpedance (kg and % of body mass)

    Time frame: Through study completion, an average of 12 weeks

  5. Physical activity (METs-min/wk)

    Using IPAQ

    Time frame: Through study completion, an average of 12 weeks

  6. Dietary (g/kg of macronutrients)

    Using a 24-total recall

    Time frame: Through study completion, an average of 12 weeks

  7. Mood state

    Mood. Participants graded a set of 29 items related to the mood on a Likert scale from 0 (not at all) to 4 (extremely) in reply to the question;How do you feel at this moment?; to assess six scales: tension, depression, anger, vigor, fatigue and confusion.

    Time frame: Through study completion, an average of 12 weeks

  8. Adverse effects

    Adverse effects. perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort.

    Time frame: Through study completion, an average of 12 weeks

07

Study locations

1 site
  • Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
    Alcalá de Henares, Madrid 28805, Spain
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06610136
Lead sponsor
University of Alcala
Responsible party
Alberto Pérez-López (Principal Investigator, University of Alcala) — Principal investigator
First posted
Sep 24, 2024
Start date
Jan 15, 2023
Primary completion
May 30, 2024
Completion
May 30, 2024
Last update
Sep 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion